IN8Bio is a clinical-stage, oncology-focused biotechnology company using ?d T cells against solid and hematological tumors. Its pipeline is built on the DeltEx platform & drug resistant immunotherapy (DRI) technology which have produced clinical candidates targeting leukemia & GBM. INB-100 is evaluating leukemia in a Ph1 study, while INB-200 & INB-400 are Ph1 and Ph2 assets evaluating GBM. INB-100 is an allogeneic DeltEx-produced cell therapy for leukemia patients undergoing HSCT transplant. Leukemia patients see a high rate of recurrence which may be effectively treated by INB-100. INB-200 is a DeltEx DRI product completing Ph1 studies in GBM. INB-400 is the successor to INB-200. It is an autologous DeltEx DRI product to treat newly diagnosed and recurrent GBM, dosing first patients in 2024. It may add autologous treatment arms in 2025. The DRI genetic modification allows it to resist chemotherapy and persist in the tumor microenvironment. While initial clinical studies target leukemia & GBM, we see DeltEx DRI as a platform that can expand beyond these initial indications. Combination studies with chemotherapy, checkpoint and PARP inhibitors may emerge in future iterations.
